LVO, CDLX among major communication services gainers; ANGH, MNY among losers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2024
0mins
Should l Buy ANGH?
Source: SeekingAlpha
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANGH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANGH
About ANGH
Anghami Inc is a United Arab Emirates based company that provides digital music entertainment technology platform in the Middle East and North Africa (MENA). The Company has catalog comprising more than 72 million songs and licensed content from Arabic labels, independent artists, and distributors, available for more than 75 million users. The Company also features music from the international labels such as Universal, Sony and Warner. The Company's services are available in English, Arabic and French. It has offices in Beirut, Dubai, Cairo and Riyadh and operates in 16 countries across MENA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Crude Oil Inventories Drop 1.934 Million Barrels, Largest Decline Since November
- Significant Inventory Decline: U.S. crude oil inventories, excluding the Strategic Petroleum Reserve, fell by 1.934 million barrels for the week ending December 26, marking the largest weekly decline since mid-November and surpassing market expectations of a 0.9 million-barrel drop, indicating a potential rebound in demand that could support oil prices.
- Jobless Claims Decrease: Initial jobless claims in the U.S. dropped by 16,000 to 199,000 for the week ending December 27, compared to market estimates of 220,000, reflecting a robust labor market that may positively impact economic recovery.
- Market Volatility: The Dow Jones index fell over 100 points on Wednesday, down 0.28%, indicating cautious market sentiment in response to economic data, although the relatively small declines in real estate and utilities sectors suggest some investor confidence remains in certain industries.
- International Market Dynamics: Asian markets closed mixed, with Hong Kong's Hang Seng Index down 0.87% while China's Shanghai Composite gained 0.09%, reflecting the impact of global economic uncertainties on market sentiment, which may lead investors to adopt more conservative strategies in the future.
See More
Intelligent Bio Solutions Partners with PREMIUM for Manufacturing
- Partnership Announcement: Intelligent Bio Solutions has entered into a manufacturing partnership with PREMIUM, aimed at enhancing production capabilities and market responsiveness, thereby expanding its influence in the biotechnology sector.
- Market Potential: This collaboration will enable Intelligent Bio Solutions to leverage PREMIUM's advanced manufacturing technologies, which is expected to significantly improve product quality and production efficiency, strengthening its position in a competitive market.
- Strategic Implications: By partnering with PREMIUM, Intelligent Bio Solutions can not only optimize its supply chain management but also accelerate time-to-market for new products, addressing the growing market demand effectively.
- Future Outlook: The establishment of this partnership signifies Intelligent Bio Solutions' ongoing expansion in the biotechnology industry, which is anticipated to generate new revenue streams and long-term growth opportunities for the company.
See More
FuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%
- Stock Offering: FuelCell Energy announced an amended sales agreement to increase the total amount of shares available for sale to $200 million, which led to an 8.9% drop in share price to $7.23 on Wednesday, indicating a negative market reaction to the dilution of shares.
- Market Reaction: The announcement of the stock offering raised investor concerns, as the significant drop in share price could impact the company's future fundraising capabilities and market confidence, particularly in the current economic climate where investors are sensitive to equity dilution.
- Funding Purpose: FuelCell Energy plans to use the proceeds from this offering to support its R&D and operational expenditures, and while the stock faces short-term pressure, successful fundraising could provide the necessary capital to drive technological innovation and market expansion in the long run.
- Industry Impact: In the context of increasing competition in the hydrogen and fuel cell industry, FuelCell Energy's stock offering may affect its reputation among investors, especially as the effectiveness of its financing strategy will directly influence its market position compared to other competitors.
See More
Anghami Inc Reports 97% Revenue Growth Tied to Warner Bros. Partnership
- Significant Revenue Growth: Anghami reported a revenue of $48.4 million for the first half of 2025, marking a 97% year-over-year increase, primarily driven by the integration with OSN+ and $43 million in subscription income, indicating strong market demand in the MENA region.
- User Base Expansion: The number of paying subscribers doubled to 3.54 million, with total registered users exceeding 120 million, demonstrating significant progress in attracting new users and enhancing market competitiveness.
- Integration Cost Pressure: Despite substantial revenue growth, Anghami incurred a loss of $37.1 million, largely due to acquisition and integration expenses related to OSN+, which may impact margins in the short term, necessitating attention to future cost controls and scale benefits.
- Market Outlook: Management anticipates continued revenue growth in the second half, but integration costs will pressure margins, with a market value around $21 million, prompting investors to weigh rapid growth against ongoing losses and execution risks.
See More
U.S. Initial Jobless Claims Drop to 199,000, Beating Estimates
- Jobless Claims Decline: Initial jobless claims fell by 16,000 to 199,000 for the week ending December 27, significantly below market expectations of 220,000, indicating resilience in the labor market and potentially boosting investor confidence.
- Tech Sector Gains: Information technology shares rose by 0.2% on Wednesday, demonstrating relative strength amid overall market declines, which may attract more capital inflows into the sector.
- Real Estate Sector Decline: Real estate stocks fell by 0.3% on Wednesday, reflecting cautious sentiment regarding the sector's outlook, which could negatively impact related companies' stock performance.
- Mixed International Markets: Asian markets closed mixed, with Hong Kong's Hang Seng Index down 0.87% while China's Shanghai Composite gained 0.09%, indicating regional economic uncertainty that may influence global investor decisions.
See More
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
See More
U.S. Crude Oil Inventories Drop 1.934 Million Barrels, Largest Decline Since November
- Significant Inventory Decline: U.S. crude oil inventories, excluding the Strategic Petroleum Reserve, fell by 1.934 million barrels for the week ending December 26, marking the largest weekly decline since mid-November and surpassing market expectations of a 0.9 million-barrel drop, indicating a potential rebound in demand that could support oil prices.
- Jobless Claims Decrease: Initial jobless claims in the U.S. dropped by 16,000 to 199,000 for the week ending December 27, compared to market estimates of 220,000, reflecting a robust labor market that may positively impact economic recovery.
- Market Volatility: The Dow Jones index fell over 100 points on Wednesday, down 0.28%, indicating cautious market sentiment in response to economic data, although the relatively small declines in real estate and utilities sectors suggest some investor confidence remains in certain industries.
- International Market Dynamics: Asian markets closed mixed, with Hong Kong's Hang Seng Index down 0.87% while China's Shanghai Composite gained 0.09%, reflecting the impact of global economic uncertainties on market sentiment, which may lead investors to adopt more conservative strategies in the future.
See More
Intelligent Bio Solutions Partners with PREMIUM for Manufacturing
- Partnership Announcement: Intelligent Bio Solutions has entered into a manufacturing partnership with PREMIUM, aimed at enhancing production capabilities and market responsiveness, thereby expanding its influence in the biotechnology sector.
- Market Potential: This collaboration will enable Intelligent Bio Solutions to leverage PREMIUM's advanced manufacturing technologies, which is expected to significantly improve product quality and production efficiency, strengthening its position in a competitive market.
- Strategic Implications: By partnering with PREMIUM, Intelligent Bio Solutions can not only optimize its supply chain management but also accelerate time-to-market for new products, addressing the growing market demand effectively.
- Future Outlook: The establishment of this partnership signifies Intelligent Bio Solutions' ongoing expansion in the biotechnology industry, which is anticipated to generate new revenue streams and long-term growth opportunities for the company.
See More
FuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%
- Stock Offering: FuelCell Energy announced an amended sales agreement to increase the total amount of shares available for sale to $200 million, which led to an 8.9% drop in share price to $7.23 on Wednesday, indicating a negative market reaction to the dilution of shares.
- Market Reaction: The announcement of the stock offering raised investor concerns, as the significant drop in share price could impact the company's future fundraising capabilities and market confidence, particularly in the current economic climate where investors are sensitive to equity dilution.
- Funding Purpose: FuelCell Energy plans to use the proceeds from this offering to support its R&D and operational expenditures, and while the stock faces short-term pressure, successful fundraising could provide the necessary capital to drive technological innovation and market expansion in the long run.
- Industry Impact: In the context of increasing competition in the hydrogen and fuel cell industry, FuelCell Energy's stock offering may affect its reputation among investors, especially as the effectiveness of its financing strategy will directly influence its market position compared to other competitors.
See More
Anghami Inc Reports 97% Revenue Growth Tied to Warner Bros. Partnership
- Significant Revenue Growth: Anghami reported a revenue of $48.4 million for the first half of 2025, marking a 97% year-over-year increase, primarily driven by the integration with OSN+ and $43 million in subscription income, indicating strong market demand in the MENA region.
- User Base Expansion: The number of paying subscribers doubled to 3.54 million, with total registered users exceeding 120 million, demonstrating significant progress in attracting new users and enhancing market competitiveness.
- Integration Cost Pressure: Despite substantial revenue growth, Anghami incurred a loss of $37.1 million, largely due to acquisition and integration expenses related to OSN+, which may impact margins in the short term, necessitating attention to future cost controls and scale benefits.
- Market Outlook: Management anticipates continued revenue growth in the second half, but integration costs will pressure margins, with a market value around $21 million, prompting investors to weigh rapid growth against ongoing losses and execution risks.
See More
U.S. Initial Jobless Claims Drop to 199,000, Beating Estimates
- Jobless Claims Decline: Initial jobless claims fell by 16,000 to 199,000 for the week ending December 27, significantly below market expectations of 220,000, indicating resilience in the labor market and potentially boosting investor confidence.
- Tech Sector Gains: Information technology shares rose by 0.2% on Wednesday, demonstrating relative strength amid overall market declines, which may attract more capital inflows into the sector.
- Real Estate Sector Decline: Real estate stocks fell by 0.3% on Wednesday, reflecting cautious sentiment regarding the sector's outlook, which could negatively impact related companies' stock performance.
- Mixed International Markets: Asian markets closed mixed, with Hong Kong's Hang Seng Index down 0.87% while China's Shanghai Composite gained 0.09%, indicating regional economic uncertainty that may influence global investor decisions.
See More
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
See More
